Eye disease , Wet age-related macular degeneration
KODKodiak Sciences Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for KSI-501 (anti-VEGF & IL-6) in Eye disease , Wet age-related macular degeneration . The expected timing is based on the latest available company guidance and may change.
DAYBREAK study: Ph3 study use an enhanced formulation of KSI-501. Initiate in mid-2024. 8/14/24- Enrollment ongoing. 3/27/25- Announce topline data in Q2 2026 11/13/25:- DAYBREAK enrollment completed. Last visit Aug 2026; KSI-501 wet AMD Ph3 topline data expected Q3 2026. 03/26/26:- DAYBREAK topline wet AMD data expected Q3 2026; potential BLA submission after readout. 03/31/26:- DAYBREAK wet AMD enrolled ~690 patients; topline remains expected in Q3 2026 (September 2026). 05/07/26:- DAYBREAK Phase 3 fully enrolled; September 2026 one-year topline wet AMD data still expected. 08/13/26:- DAYBREAK one-year Phase 3 topline data for KSI-501 will be reported in September 2026.
Verification
Confirm timing and program details against the company announcement or filing.